| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H30N4O2 |
| Molecular Weight | 430.542 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CCC2=C(N1)N=C(OCCCCN3CCN(CC3)C4=C5C=CC=CC5=CC=C4)C=C2
InChI
InChIKey=QGNOXTFZOLDODX-UHFFFAOYSA-N
InChI=1S/C26H30N4O2/c31-24-12-10-21-11-13-25(28-26(21)27-24)32-19-4-3-14-29-15-17-30(18-16-29)23-9-5-7-20-6-1-2-8-22(20)23/h1-2,5-9,11,13H,3-4,10,12,14-19H2,(H,27,28,31)
Pfizer was developing NPBN (PF 217830), an orally administered dopamine D2 and serotonin 5-HT1A partial agonist and 5-HT2A antagonist, for the treatment of schizophrenia. PF-217830 was discontinued from development due to either non-optimal pharmacokinetic properties or insufficient therapeutical efficacy.
CNS Activity
Originator
Approval Year
PubMed
ACTIVE MOIETY
